Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Upgrades
升級
According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:SEEL) was changed from Neutral to Buy. For the second quarter, Seelos Therapeutics had an EPS of $0.08, compared to year-ago quarter EPS of $0.08. The current stock performance of Seelos Therapeutics shows a 52-week-high of $6.60 and a 52-week-low of $0.56. Moreover, at the end of the last trading period, the closing price was at $2.09.
For Yandex NV (NASDAQ:YNDX), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, Yandex had an EPS of $0.04, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $82.62 and a 52-week-low of $55.62. At the end of the last trading period, Yandex closed at $80.20.
SVB Leerink upgraded the previous rating for Sanofi SA (NASDAQ:SNY) from Market Perform to Outperform. Sanofi earned $1.66 in the second quarter, compared to $1.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $54.26 and a 52-week-low of $44.76. Sanofi closed at $47.94 at the end of the last trading period.
According to JMP Securities, the prior rating for Viant Technology Inc (NASDAQ:DSP) was changed from Market Perform to Market Outperform. Interestingly, in the second quarter, Viant Technology's EPS was $0.06. The current stock performance of Viant Technology shows a 52-week-high of $69.16 and a 52-week-low of $11.49. Moreover, at the end of the last trading period, the closing price was at $12.69.
JMP Securities upgraded the previous rating for Box Inc (NYSE:BOX) from Market Perform to Market Outperform. Box earned $0.21 in the second quarter, compared to $0.18 in the year-ago quarter. The current stock performance of Box shows a 52-week-high of $27.41 and a 52-week-low of $15.07. Moreover, at the end of the last trading period, the closing price was at $25.24.
Atlantic Equities upgraded the previous rating for Bath & Body Works Inc (NYSE:BBWI) from Neutral to Overweight. In the second quarter, Bath & Body Works earned $1.34.Bath & Body Works closed at $67.39 at the end of the last trading period.
For Icon PLC (NASDAQ:ICLR), JP Morgan upgraded the previous rating of Neutral to Overweight. For the second quarter, Icon had an EPS of $2.12, compared to year-ago quarter EPS of $1.20. At the moment, the stock has a 52-week-high of $284.20 and a 52-week-low of $168.76. Icon closed at $283.04 at the end of the last trading period.
For National Instruments Corp (NASDAQ:NATI), Goldman Sachs upgraded the previous rating of Neutral to Buy. For the second quarter, National Instruments had an EPS of $0.35, compared to year-ago quarter EPS of $0.26. At the moment, the stock has a 52-week-high of $47.40 and a 52-week-low of $30.42. National Instruments closed at $41.16 at the end of the last trading period.
根據Roth Capital的説法，之前的評級為Seelos治療公司(納斯達克市場代碼：SEEL)從中性改為買入。第二季度，Seelos治療公司的每股收益為0.08美元，而去年同期為0.08美元。Seelos Treeutics目前的股票表現顯示，52周高點為6.60美元，52周低點為0.56美元。而且，在上個交易期結束時，收盤價為2.09美元。
為Yandex NV(Nasdaq：YNDX)，瑞銀將此前中性評級上調至買入。第二季度，Yandex的每股收益為0.04美元，而去年同期為0.08美元。該股目前的52周高點為82.62美元，52周低點為55.62美元。上交易期尾盤，Yandex收報80.20美元。
SVB Leerink上調了之前的評級賽諾菲安萬特(納斯達克股票代碼：SNY)從市場表現到強於大盤。賽諾菲第二季度盈利1.66美元，而去年同期為1.41美元。目前，該股的52周高點為54.26美元，52周低點為44.76美元。賽諾菲上交易期尾盤收報47.94美元。
根據JMP證券的説法，之前的評級為Viant Technology Inc.(納斯達克市場代碼：DSP)從市場表現改為市場表現好於市場。有趣的是，在第二季度，Viant Technology的每股收益為0.06美元。Viant Technology目前的股票表現顯示，52周高點為69.16美元，52周低點為11.49美元。而且，在上個交易期結束時，收盤價為12.69美元。
JMP證券上調了之前對該公司的評級Box Inc.(紐約證券交易所股票代碼：BOX)從市場表現到市場表現優異。Box第二季度盈利0.21美元，而去年同期為0.18美元。Box目前的股票表現顯示，52周高點為27.41美元，52周低點為15.07美元。而且，在上個交易期結束時，收盤價為25.24美元。
大西洋證券公司上調了之前的評級，Bath&Body Works Inc.(紐約證券交易所股票代碼：BBWI)從中性到超重。在第二季度，Bath&Body Works賺了1.34美元，Bath&Body Works在上個交易期結束時收於67.39美元。
為圖標PLC(納斯達克股票代碼：ICLR)，摩根大通將之前的中性評級上調至加碼。第二季度，Icon的每股收益為2.12美元，而去年同期為1.20美元。目前，該股的52周高點為284.20美元，52周低點為168.76美元。ICON上交易日尾盤報283.04美元。
為美國國家儀器公司(National Instruments Corp)(納斯達克股票代碼：Nati)，高盛將之前中性的評級上調至買入。第二季度，National Instruments的每股收益為0.35美元，而去年同期為0.26美元。目前，該股的52周高點為47.40美元，52周低點為30.42美元。National Instruments上一交易期尾盤報41.16美元。
See all analyst ratings upgrades.
查看所有分析師評級升級。
Downgrades
降級
According to Credit Suisse, the prior rating for Altice USA Inc (NYSE:ATUS) was changed from Outperform to Neutral. In the second quarter, Altice USA showed an EPS of $0.51, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $38.30 and a 52-week-low of $19.74. Altice USA closed at $20.58 at the end of the last trading period.
B of A Securities downgraded the previous rating for Hyatt Hotels Corp (NYSE:H) from Neutral to Underperform. Hyatt Hotels earned $1.15 in the second quarter, compared to $1.80 in the year-ago quarter. The current stock performance of Hyatt Hotels shows a 52-week-high of $92.22 and a 52-week-low of $51.21. Moreover, at the end of the last trading period, the closing price was at $79.76.
For American Water Works Co Inc (NYSE:AWK), B of A Securities downgraded the previous rating of Neutral to Underperform. American Water Works Co earned $1.14 in the second quarter, compared to $0.97 in the year-ago quarter. The current stock performance of American Water Works Co shows a 52-week-high of $189.35 and a 52-week-low of $131.01. Moreover, at the end of the last trading period, the closing price was at $176.79.
JP Morgan downgraded the previous rating for Talis Biomedical Corp (NASDAQ:TLIS) from Neutral to Underweight. Interestingly, in the second quarter, Talis Biomedical's EPS was $2.51. The stock has a 52-week-high of $33.90 and a 52-week-low of $6.81. At the end of the last trading period, Talis Biomedical closed at $7.04.
For Zymergen Inc (NASDAQ:ZY), JP Morgan downgraded the previous rating of Neutral to Underweight. Interestingly, in the second quarter, Zymergen's EPS was $1.30. The current stock performance of Zymergen shows a 52-week-high of $52.00 and a 52-week-low of $7.85. Moreover, at the end of the last trading period, the closing price was at $13.40.
According to Goldman Sachs, the prior rating for Lordstown Motors Corp (NASDAQ:RIDE) was changed from Neutral to Sell. In the second quarter, Lordstown Motors showed an EPS of $0.61, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $31.57 and a 52-week-low of $4.77. At the end of the last trading period, Lordstown Motors closed at $7.57.
Raymond James downgraded the previous rating for Altice USA Inc (NYSE:ATUS) from Outperform to Market Perform. For the second quarter, Altice USA had an EPS of $0.51, compared to year-ago quarter EPS of $0.19. At the moment, the stock has a 52-week-high of $38.30 and a 52-week-low of $19.74. Altice USA closed at $20.58 at the end of the last trading period.
根據瑞士信貸(Credit Suisse)的説法，之前的評級為Altice USA Inc.(紐約證券交易所代碼：ATUS)從強於大盤改為中性。第二季度，Altice USA的每股收益為0.51美元，而去年同期為0.19美元。目前，該股的52周高點為38.30美元，52周低點為19.74美元。Altice USA上交易日尾盤報20.58美元。
B of A Securities下調之前的評級為凱悦酒店集團(紐約證券交易所股票代碼：H)從中性到表現不佳。凱悦酒店第二季度盈利1.15美元，而去年同期為1.80美元。凱悦酒店目前的股票表現顯示52周高點92.22美元和52周低點51.21美元。而且，在上個交易期結束時，收盤價為79.76美元。
為美國水務公司(紐約證券交易所代碼：AWK)，B of A Securities將此前評級下調至中性至表現不佳。美國水務公司(American Water Works Co)第二季度盈利1.14美元，而去年同期為0.97美元。美國水務公司(American Water Works Co)目前的股票表現顯示，52周高點為189.35美元，52周低點為131.01美元。而且，在上個交易期結束時，收盤價為176.79美元。
摩根大通下調了之前的評級為塔利斯生物醫學公司(納斯達克股票代碼：TLIS)從中性到減持。有趣的是，在第二季度，Talis Biomedical的每股收益為2.51美元。該股目前的52周高點為33.90美元，52周低點為6.81美元。上交易期尾盤，Talis Biomedical收報7.04美元。
為Zymergen Inc.(納斯達克股票代碼：ZY)，摩根大通將之前的評級下調至中性至減持。有趣的是，在第二季度，Zymergen的每股收益為1.30美元。Zymergen目前的股票表現顯示，52周高點為52.00美元，52周低點為7.85美元。而且，在上個交易期結束時，收盤價為13.40美元。
根據高盛(Goldman Sachs)的説法，之前的評級為洛德斯敦汽車公司(Lordstown Motors Corp)(納斯達克股票代碼：RIDE)從中性改為賣出。第二季度，Lordstown Motors的每股收益為0.61美元，而去年同期為0.11美元。該股目前的52周高點為31.57美元，52周低點為4.77美元。上一交易期尾盤，Lordstown Motors收報7.57美元。
雷蒙德·詹姆斯(Raymond James)下調了之前的評級Altice USA Inc.(紐約證券交易所股票代碼：ATUS)從強於大盤到市場表現。第二季度，Altice USA的每股收益為0.51美元，而去年同期為0.19美元。目前，該股的52周高點為38.30美元，52周低點為19.74美元。Altice USA上交易日尾盤報20.58美元。
See all analyst ratings downgrades.
查看所有分析師評級下調。
Initiations
啟蒙行動
With a Hold rating, Vertical Research initiated coverage on Ecolab Inc (NYSE:ECL). The price target seems to have been set at $189.00 for Ecolab. In the second quarter, Ecolab showed an EPS of $1.22, compared to $0.65 from the year-ago quarter. The current stock performance of Ecolab shows a 52-week-high of $231.25 and a 52-week-low of $181.25. Moreover, at the end of the last trading period, the closing price was at $223.77.
With a Buy rating, Craig-Hallum initiated coverage on dMY Technology Group Inc IV (NYSE:DMYQ). The price target seems to have been set at $15.00 for dMY Technology Group Inc. The current stock performance of dMY Technology Group Inc shows a 52-week-high of $10.48 and a 52-week-low of $9.57. Moreover, at the end of the last trading period, the closing price was at $9.95.
With a Buy rating, Maxim Group initiated coverage on SPI Energy Co Ltd (NASDAQ:SPI). The price target seems to have been set at $12.00 for SPI Energy. At the moment, the stock has a 52-week-high of $28.71 and a 52-week-low of $4.59. SPI Energy closed at $5.36 at the end of the last trading period.
With a Buy rating, Canaccord Genuity initiated coverage on Pacific Biosciences of California Inc (NASDAQ:PACB). The price target seems to have been set at $45.00 for Pacific Biosciences. In the second quarter, Pacific Biosciences showed an EPS of $0.21, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $53.69 and a 52-week-low of $8.05. At the end of the last trading period, Pacific Biosciences closed at $25.58.
Cantor Fitzgerald initiated coverage on Sierra Oncology Inc (NASDAQ:SRRA) with an Overweight rating. The price target for Sierra Oncology is set to $33.00. For the second quarter, Sierra Oncology had an EPS of $1.41, compared to year-ago quarter EPS of $1.58. The current stock performance of Sierra Oncology shows a 52-week-high of $23.85 and a 52-week-low of $10.02. Moreover, at the end of the last trading period, the closing price was at $22.45.
With an Outperform rating, SVB Leerink initiated coverage on UnitedHealth Group Inc (NYSE:UNH). The price target seems to have been set at $480.00 for UnitedHealth Group. In the second quarter, UnitedHealth Group showed an EPS of $4.70, compared to $7.12 from the year-ago quarter. The stock has a 52-week-high of $431.36 and a 52-week-low of $289.64. At the end of the last trading period, UnitedHealth Group closed at $407.08.
SVB Leerink initiated coverage on Mednax Inc (NYSE:MD) with a Market Perform rating. The price target for Mednax is set to $29.00. Mednax earned $0.41 in the second quarter, compared to $0.32 in the year-ago quarter. The current stock performance of Mednax shows a 52-week-high of $35.67 and a 52-week-low of $12.47. Moreover, at the end of the last trading period, the closing price was at $28.85.
With a Market Perform rating, Keefe, Bruyette & Woods initiated coverage on Jackson Financial Inc (NYSE:JXN). The price target seems to have been set at $30.00 for Jackson Financial. In the second quarter, Jackson Financial earned $6.74. Jackson Financial closed at $27.90 at the end of the last trading period.
SVB Leerink initiated coverage on AdaptHealth Corp (NASDAQ:AHCO) with an Outperform rating. The price target for AdaptHealth is set to $30.00. For the second quarter, AdaptHealth had an EPS of $0.17, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $41.58 and a 52-week-low of $19.17. AdaptHealth closed at $23.00 at the end of the last trading period.
SVB Leerink initiated coverage on Acadia Healthcare Co Inc (NASDAQ:ACHC) with an Outperform rating. The price target for Acadia Healthcare Co is set to $85.00. In the second quarter, Acadia Healthcare Co showed an EPS of $0.71, compared to $0.54 from the year-ago quarter. The current stock performance of Acadia Healthcare Co shows a 52-week-high of $68.65 and a 52-week-low of $27.07. Moreover, at the end of the last trading period, the closing price was at $65.15.
SVB Leerink initiated coverage on Tenet Healthcare Corp (NYSE:THC) with a Market Perform rating. The price target for Tenet Healthcare is set to $80.00. For the second quarter, Tenet Healthcare had an EPS of $1.59, compared to year-ago quarter EPS of $1.26. At the moment, the stock has a 52-week-high of $76.16 and a 52-week-low of $21.34. Tenet Healthcare closed at $71.39 at the end of the last trading period.
SVB Leerink initiated coverage on Humana Inc (NYSE:HUM) with an Outperform rating. The price target for Humana is set to $494.00. Humana earned $6.89 in the second quarter, compared to $12.56 in the year-ago quarter. The current stock performance of Humana shows a 52-week-high of $475.44 and a 52-week-low of $370.22. Moreover, at the end of the last trading period, the closing price was at $398.91.
SVB Leerink initiated coverage on Cigna Corp (NYSE:CI) with a Market Perform rating. The price target for Cigna is set to $220.00. For the second quarter, Cigna had an EPS of $5.24, compared to year-ago quarter EPS of $5.81. The stock has a 52-week-high of $272.81 and a 52-week-low of $158.84. At the end of the last trading period, Cigna closed at $203.89.
SVB Leerink initiated coverage on Amedisys Inc (NASDAQ:AMED) with a Market Perform rating. The price target for Amedisys is set to $170.00. For the second quarter, Amedisys had an EPS of $1.69, compared to year-ago quarter EPS of $1.34. The stock has a 52-week-high of $325.12 and a 52-week-low of $154.52. At the end of the last trading period, Amedisys closed at $155.35.
SVB Leerink initiated coverage on HCA Healthcare Inc (NYSE:HCA) with an Outperform rating. The price target for HCA Healthcare is set to $320.00. In the second quarter, HCA Healthcare showed an EPS of $4.37, compared to $3.23 from the year-ago quarter. The stock has a 52-week-high of $263.92 and a 52-week-low of $114.38. At the end of the last trading period, HCA Healthcare closed at $256.33.
With a Market Perform rating, SVB Leerink initiated coverage on Anthem Inc (NYSE:ANTM). The price target seems to have been set at $403.00 for Anthem. For the second quarter, Anthem had an EPS of $7.03, compared to year-ago quarter EPS of $9.20. The current stock performance of Anthem shows a 52-week-high of $406.00 and a 52-week-low of $244.10. Moreover, at the end of the last trading period, the closing price was at $381.33.
With an Outperform rating, SVB Leerink initiated coverage on Agilon Health Inc (NYSE:AGL). The price target seems to have been set at $37.00 for Agilon Health. Agilon Health earned $0.79 in the second quarter. At the moment, the stock has a 52-week-high of $44.83 and a 52-week-low of $26.50. Agilon Health closed at $28.10 at the end of the last trading period.
JP Morgan initiated coverage on Omeros Corp (NASDAQ:OMER) with a Neutral rating. The price target for Omeros is set to $15.00. Omeros earned $0.46 in the second quarter, compared to $0.61 in the year-ago quarter. The current stock performance of Omeros shows a 52-week-high of $23.85 and a 52-week-low of $9.25. Moreover, at the end of the last trading period, the closing price was at $15.88.
With a Buy rating, Jefferies initiated coverage on Kinnate Biopharma Inc (NASDAQ:KNTE). The price target seems to have been set at $46.00 for Kinnate Biopharma. Kinnate Biopharma earned $0.49 in the second quarter, compared to $2.05 in the year-ago quarter. The current stock performance of Kinnate Biopharma shows a 52-week-high of $48.75 and a 52-week-low of $17.58. Moreover, at the end of the last trading period, the closing price was at $22.67.
With a Neutral rating, JP Morgan initiated coverage on Airbnb Inc (NASDAQ:ABNB). The price target seems to have been set at $170.00 for Airbnb. For the second quarter, Airbnb had an EPS of $0.11, compared to year-ago quarter EPS of $1.30. The current stock performance of Airbnb shows a 52-week-high of $219.94 and a 52-week-low of $121.50. Moreover, at the end of the last trading period, the closing price was at $175.88.
在持有評級的情況下，Vertical Research啟動了對Ecolab Inc.(紐約證券交易所代碼：ECL)。Ecolab的目標價似乎被設定在189.00美元。第二季度，Ecolab顯示每股收益為1.22美元，而去年同期為0.65美元。Ecolab目前的股票表現顯示，52周高點為231.25美元，52周低點為181.25美元。而且，在上個交易期結束時，收盤價為223.77美元。
憑藉買入評級，Craig-Hallum在DMY科技集團公司IV(紐約證券交易所代碼：DMYQ)。DMY科技集團(DMY Technology Group Inc)的目標價似乎被設定在15.00美元。目前DMY科技集團(DMY Technology Group Inc)的股價表現顯示，其股價創下52周高位10.48美元和52周低點9.57美元。而且，在上個交易期結束時，收盤價為9.95美元。
憑藉買入評級，Maxim Group在陽光動力(納斯達克市場代碼：SPI)。SPI Energy的目標價似乎被設定在12.00美元。目前，該股的52周高點為28.71美元，52周低點為4.59美元。SPI Energy上一交易期尾盤報5.36美元。
憑藉買入評級，Canaccel Genuity在加州太平洋生物科學公司(納斯達克股票代碼：PACB)太平洋生物科學公司的目標價格似乎被設定在45.00美元。太平洋生物科學公司第二季度的每股收益為0.21美元，而去年同期為0.15美元。該股52周高點為53.69美元，52周低點為8.05美元。太平洋生物科學上交易期尾盤收報25.58美元。
康託·菲茨傑拉德(Cantor Fitzgerald)在塞拉腫瘤公司(納斯達克股票代碼：SRRA)，評級為增持。Sierra Oncology的目標價格定為33.00美元。第二季度，Sierra Oncology的每股收益為1.41美元，而去年同期為1.58美元。Sierra Oncology目前的股票表現顯示，52周高點為23.85美元，52周低點為10.02美元。而且，在上個交易期結束時，收盤價為22.45美元。
憑藉強於大盤的評級，SVB Leerink在聯合健康(紐約證券交易所市場代碼：UNH)。UnitedHealth Group的目標價格似乎被設定在480.00美元。UnitedHealth Group第二季度每股收益為4.70美元，而去年同期為7.12美元。該股目前的52周高點為431.36美元，52周低點為289.64美元。上一交易期尾盤，聯合健康集團收報407.08美元。
SVB Leerink在MEDNAX公司(紐約證券交易所股票代碼：MD)具有市場表現評級。Mednax的目標價定為29.00美元。MEDNAX第二季度盈利0.41美元，而去年同期為0.32美元。Mednax目前的股票表現顯示，52周高點為35.67美元，52周低點為12.47美元。而且，在上個交易期結束時，收盤價為28.85美元。
憑藉市場表現評級，Keefe，Bruyette&Woods在傑克遜金融公司(紐約證券交易所代碼：JXN)。傑克遜金融公司的目標價似乎被設定在30.00美元。在第二季度，傑克遜金融公司賺了6.74美元。Jackson Financial上一交易期尾盤報27.90美元。
SVB Leerink在AdaptHealth公司(納斯達克股票代碼：AHCO)，評級優於大盤。AdaptHealth的目標價設為30.00美元。第二季度，AdaptHealth的每股收益為0.17美元，而去年同期為0.08美元。目前，該股的52周高點為41.58美元，52周低點為19.17美元。AdaptHealth上交易期尾盤收報23.00美元。
SVB Leerink在阿卡迪亞醫療保健公司(Acadia Healthcare Co Inc.)(納斯達克股票代碼：ACHC)，評級為跑贏大盤。阿卡迪亞醫療保健公司(Acadia Healthcare Co)的目標價定為85.00美元。阿卡迪亞醫療保健公司(Acadia Healthcare Co)第二季度每股收益為0.71美元，而去年同期為0.54美元。阿卡迪亞醫療保健公司(Acadia Healthcare Co)目前的股票表現顯示，其股價為68.65美元的52周高位和27.07美元的52周低點。而且，在上個交易期結束時，收盤價為65.15美元。
SVB Leerink在Tenet Healthcare Corp(紐約證券交易所股票代碼：THC)，市場表現評級。Tenet Healthcare的目標價定為80.00美元。第二季度，Tenet Healthcare的每股收益為1.59美元，而去年同期為1.26美元。目前，該股的52周高點為76.16美元，52周低點為21.34美元。Tenet Healthcare上交易日尾盤收報71.39美元。
SVB Leerink在Humana Inc.(紐約證券交易所股票代碼：HUM)，評級優於大盤。Humana的目標價定為494.00美元。Humana第二季度的利潤為6.89美元，而去年同期為12.56美元。Humana目前的股票表現顯示，52周高點為475.44美元，52周低點為370.22美元。而且，在上個交易期結束時，收盤價為398.91美元。
SVB Leerink在信諾(紐約證券交易所股票代碼：CI)具有市場表現評級。信諾的目標價定為220.00美元。信諾第二季度每股收益為5.24美元，而去年同期為5.81美元。該股目前的52周高點為272.81美元，52周低點為158.84美元。上交易期尾盤，信諾收報203.89美元。
SVB Leerink在Amedisys Inc.(納斯達克股票代碼：AMED)，市場表現評級。美國運通的目標價定為170.00美元。第二季度，Amedisys的每股收益為1.69美元，而去年同期為1.34美元。該股目前的52周高點為325.12美元，52周低點為154.52美元。上一交易期尾盤，美國運通收報155.35美元。
SVB Leerink在HCA控股(紐約證券交易所股票代碼：HCA)，評級優於大盤。HCA Healthcare的目標價格定為320.00美元。第二季度，HCA Healthcare顯示每股收益為4.37美元，而去年同期為3.23美元。該股目前的52周高點為263.92美元，52周低點為114.38美元。上交易期尾盤，HCA Healthcare收報256.33美元。
憑藉市場表現評級，SVB Leerink在Anthem(紐約證券交易所代碼：ANTM)。國歌的目標價格似乎被設定在403.00美元。第二季度，國歌的每股收益為7.03美元，而去年同期為9.20美元。國歌目前的股票表現顯示，52周高點為406.00美元，52周低點為244.10美元。而且，在上個交易期結束時，收盤價為381.33美元。
憑藉強於大盤的評級，SVB Leerink在安捷倫健康公司(Agilon Health Inc.)(紐約證券交易所代碼：AGL)。安捷倫健康的目標價格似乎被設定在37.00美元。安捷倫健康第二季度盈利0.79美元。目前，該股的52周高點為44.83美元，52周低點為26.50美元。安捷倫健康上交易期尾盤收報28.10美元。
摩根大通在Omeros公司(納斯達克股票代碼：OMER)評級為中性。Omeros的目標價定為15.00美元。Omeros第二季度盈利0.46美元，而去年同期為0.61美元。目前Omeros的股票表現顯示，52周高點為23.85美元，52周低點為9.25美元。而且，在上個交易期結束時，收盤價為15.88美元。
在獲得買入評級的情況下，Jefferies在Kinnate Biophma Inc.(納斯達克市場代碼：KNTE)Kinnate Biophma的目標價似乎被設定在46.00美元。Kinnate Biophma第二季度盈利0.49美元，而去年同期為2.05美元。Kinnate Biophma目前的股票表現顯示，52周高點為48.75美元，52周低點為17.58美元。而且，在上個交易期結束時，收盤價為22.67美元。
評級為中性，摩根大通在愛彼迎股份有限公司(納斯達克股票代碼：ABNB)愛彼迎的目標價似乎被設定在170.00美元。第二季度，愛彼迎的每股收益為0.11美元，而去年同期為1.3美元。愛彼迎目前的股票表現顯示，52周高點為219.94美元，52周低點為121.50美元。而且，在上個交易期結束時，收盤價為175.88美元。
See all analyst ratings initiations.
查看所有分析師評級啟動。